{"groups":[{"description":"Participants received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"FG000","title":"Romidepsin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Compassionate Use"},{"reasons":[{"groupId":"FG000","numSubjects":"83"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"24"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Other Reasons (Miscellaneous)"}],"milestones":[{"achievements":[{"comment":"Represents the number of patients who received any amount of study drug.","groupId":"FG000","numSubjects":"131"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"98"}],"type":"Discontinued Prior to or During Cycle 6"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"Discontinued at End of or After Cycle 6"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"131"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}